Medicenna Therapeutics Corp. (TSE:MDNA – Get Free Report) fell 2.4% during trading on Thursday . The company traded as low as C$2.05 and last traded at C$2.05. 39,581 shares were traded during mid-day trading, a decline of 64% from the average session volume of 108,453 shares. The stock had previously closed at C$2.10.
Medicenna Therapeutics Price Performance
The company has a current ratio of 2.51, a quick ratio of 4.65 and a debt-to-equity ratio of 0.06. The business has a 50-day moving average of C$2.14 and a 200 day moving average of C$2.09. The firm has a market capitalization of C$156.68 million, a PE ratio of -5.39 and a beta of 1.26.
Medicenna Therapeutics Company Profile
Medicenna Therapeutics Corp., an immunotherapy company, engages in the development and commercialization of Superkines and empowered Superkines for the treatment of cancer and other diseases. It develops MDNA55, an interleukin- 4 (IL-4) EC for the treatment of recurrent glioblastoma, as well as for brain tumors.
Read More
- Five stocks we like better than Medicenna Therapeutics
- Stock Splits, Do They Really Impact Investors?
- When Is the Best Time to Invest in Mutual Funds?
- What is MarketRank™? How to Use it
- Is NVIDIA Stock in a Correction or Consolidation?
- Why Understanding Call Option Volume is Essential to Successful Options Trading
- 3 Oversold Stocks with Big RSI Rebound Potential
Receive News & Ratings for Medicenna Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Medicenna Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
